<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00357669</url>
  </required_header>
  <id_info>
    <org_study_id>N01187</org_study_id>
    <secondary_id>2006-000169-12</secondary_id>
    <nct_id>NCT00357669</nct_id>
  </id_info>
  <brief_title>Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease in Adolescents and Adults</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Study to Evaluate the Efficacy and Safety of Brivaracetam Used as Adjunctive Treatment for 12 Weeks in Adolescent and Adult Patients (≥16 Years) With Genetically Ascertained Unverricht-Lundborg Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Pharma SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will compare the efficacy and safety of brivaracetam with placebo in patients with
      Unverricht-Lundborg disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent reduction from baseline on the Action Myoclonus score (Unified Myoclonus Rating Scale (UMRS) Section 4) at the end of the Treatment Period</measure>
    <time_frame>End of treatment period (Week 14 or early discontinuation visit)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent reduction from baseline on the functional disability score (UMRS Section 5) at the end of the Treatment Period</measure>
    <time_frame>End of treatment period (week 14 or early discontinuation visit)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent reduction from baseline on the stimulus sensitivity score (UMRS Section 3) at the end of the Treatment Period</measure>
    <time_frame>End of treatment period (week 14 or early discontinuation visit)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent reduction from baseline on the myoclonus patient questionnaire (UMRS Section 1) at the end of the Treatment Period</measure>
    <time_frame>End of treatment period (week 14 or early discontinuation visit)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Evaluation Scale by Investigator (I-GES) at the end of the Treatment Period</measure>
    <time_frame>End of treatment period (week 14 or early discontinuation visit)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Unverricht-Lundborg Disease</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Brivaracetam 50 mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BRV 50 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Brivaracetam 150 mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BRV 150 mg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brivaracetam 25 mg</intervention_name>
    <description>Active Substance: Brivaracetam
Pharmaceutical Form: Tablet
Concentration: 25 mg
Route of Administration: Oral use</description>
    <arm_group_label>Brivaracetam 50 mg/day</arm_group_label>
    <arm_group_label>Brivaracetam 150 mg/day</arm_group_label>
    <other_name>ucb34714</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brivaracetam 50 mg</intervention_name>
    <description>Active Substance: Brivaracetam
Pharmaceutical Form: Tablet
Concentration: 50 mg
Route of Administration: Oral use</description>
    <arm_group_label>Brivaracetam 50 mg/day</arm_group_label>
    <arm_group_label>Brivaracetam 150 mg/day</arm_group_label>
    <other_name>ucb34714</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Active Substance: Placebo Pharmaceutical Form: Tablet
Concentration: 25 mg and 50 mg
Route of Administration: Oral use</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with diagnosed Unverricht-Lundborg disease (ULD) ascertained by appropriate
             genetic testing for a homozygous or compound heterozygous mutation in the Cystatin B
             (CSTB) gene

          -  Subjects with moderate to severe myoclonus documented by an Action Myoclonus sum score
             of ≥ 30 (evaluation by investigator)

          -  Subjects currently being or having been treated with clonazepam up to the maximum
             recommended daily dose of 20 mg or up to their individual optimal dose as assessed by
             the investigator

          -  Subjects currently being or having been treated with valproate up to the maximum
             recommended daily dose 60 mg/kg or serum levels of 100 mcg/ml or up to their
             individual optimal dose as specified by the investigator

        Exclusion Criteria:

          -  Subjects currently on felbamate or having been on felbamate within less than 18 months
             prior to Visit 1

          -  Subjects currently treated with phenytoin or having been on phenytoin in the last
             month prior to Visit 1

          -  Subjects currently on vigabatrine. Subjects having been on vigabatrine if no visual
             fields examination report available including standard static (Humphrey or Octopus) or
             cinetic perimetry (Goldman)

          -  Subject taking any drug with possible central nervous system (CNS) effects

          -  Subjects taking any drug that may significantly influence the metabolism of BRV (CYP2C
             or CYP3A potent inducers/inhibitors)

          -  Known clinically significant acute or chronic illness or illness which may impair
             reliable participation in the trial, necessitate the use of medication not allowed by
             protocol or represent a safety risk in the Investigator's opinion

          -  Subjects with history of severe adverse hematological reaction to any drug

          -  Impaired hepatic function: ALAT/SGPT, ASAT/SGOT, alkaline phosphatase, GGT value of
             more than three times the upper limit of the reference range

          -  History of suicide attempt during the last 5 years

          -  Subject with suicidal ideations within the last year or at risk of suicide attempt
             unless cleared by written confirmation from a psychiatrist and approved by the UCB
             physician

          -  Ongoing psychiatric disorder other than mild controlled disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Clinical Trial Call Center</last_name>
    <role>Study Director</role>
    <affiliation>+1 877 822 9493 (UCB)</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Kuopio</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montpellier Cedex 5</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Messina</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Heemstede</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Heeze</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St Pierre Cedex</city>
        <country>Réunion</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Goteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tunis</city>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>France</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Réunion</country>
    <country>Sweden</country>
    <country>Tunisia</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 25, 2006</study_first_submitted>
  <study_first_submitted_qc>July 25, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2006</study_first_posted>
  <last_update_submitted>May 15, 2015</last_update_submitted>
  <last_update_submitted_qc>May 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Unverricht-Lundborg disease</keyword>
  <keyword>Baltic myoclonus</keyword>
  <keyword>progressive myoclonic epilepsies</keyword>
  <keyword>myoclonus</keyword>
  <keyword>brivaracetam</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Unverricht-Lundborg Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brivaracetam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

